News & Resources

SOUTHBOROUGH, MA (June 8, 2016) — Corrona, a leader in real world evidence and consulting in the auto-immune field, will be represented by 13 clinical researchers who will be showcasing their research at the Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London, UK. The presentations represent the efforts of 654 practicing rheumatologists in the US who, over the last 15 years, have collected longitudinal randomized controlled trial quality clinical data on patients with rheumatic diseases. In particular, 2 abstracts were accepted for podium presentations and 13 as posters, 3 of which will be highlighted on poster tours. These efforts add to Corrona’s growing number of scientific publications in peer-reviewed journals, with over 300 abstracts and 80 manuscripts.

“The Corrona team appreciates that the continued data collection efforts of our rheumatology investigators have provided the foundation for our research programs in areas such as comparative effectiveness and safety of novel therapies.” — Jeff Greenberg, MD, MPH, Chief Scientific Officer, Corrona, LLC.

Work presented at the meeting will be derived from Corrona’s rheumatoid arthritis and psoriatic arthritis/spondyloarthritis registries. The podium presentations will focus on the impact of rheumatoid arthritis disease activity on infection risk and explore biomarkers’ ability to predict response to biologic medications. Other topics being explored in the rheumatoid arthritis patient population include: trends in disease activity and treatment patterns, delays in treatment acceleration, outcomes related to a treat to target strategy, the influence of comorbidities, and a comparative effectiveness evaluation of disease modifying anti-rheumatic drugs. In psoriatic arthritis/spondyloarthritis, presentations focus on: characterization of unique patient subgroups, treatment patterns, evaluating biologic medication persistency, and rebounding of symptoms following achievement of low disease activity and biologic discontinuation.

About Corrona

Corrona was founded in 2001 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides longitudinal clinical data, patient reported measures, and research results to all biopharmaceutical companies with an interest in autoimmune diseases. Corrona data analysis has provided a rich framework in which to explore topics such as comparative effectiveness, post market safety reporting, and commercial applications. Corrona is advised by experienced academic and clinical physicians throughout the country with a wide range of expertise.

For any questions contact us at info@corrona.org or call us at (508) 408-5435.

PORTLAND, Ore. (May 2, 2016) — The Corrona Psoriasis Registry announced it will track the drug safety reporting for ixekizumab, a new biologic medication by Eli Lilly and Company (NYSE: LLY) that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, the leading sponsor of registries in autoimmune disease.

The registry will enroll at least 4,000 people with psoriasis on ixekizumab and follow their treatment for at least eight years. Over 1,200 people on various psoriasis medications from 100 sites have joined within the first year of the registry. Registry participation numbers are expected to grow to more than 10,000 people with moderate-to-severe psoriasis on biologics or systemic medications and 200 sites. By collecting and analyzing data from thousands of people over many years, the registry will help researchers compare the safety and effectiveness of psoriasis therapies, study other diseases and medical conditions associated with psoriasis, and better understand the natural course of the disease.

“This is an exciting time for patients with psoriasis as new treatments become available, and this registry will provide the long-term data we need to understand the safety and effectiveness of these therapies,” said Dr. Bruce Strober, professor and chair of University of Connecticut Health Center Department of Dermatology and scientific co-director of the registry. “The information collected will also provide valuable insights into the relationship between psoriasis and other diseases, as well as the impact of psoriasis and its treatments on quality of life.”

Lilly is the second drug manufacturer to select the Corrona Psoriasis Registry to meet its regulatory post-approval safety commitments in psoriasis. “Particularly for newly approved drugs, these long-term safety studies by an independent organization can help provide patients, physicians and regulators with the long-term safety data they need,” said Dr. Jeff Greenberg, chief scientific officer of Corrona.

“Ixekizumab was approved by the FDA based on safety information drawn from a database of 4,204 patients with moderate-to-severe plaque psoriasis who volunteered in both controlled and uncontrolled clinical trials, and physicians are just beginning to use it in practice,” said Nayan Acharya, M.D., senior medical director, Cardiovascular, Dermatology and Inflammation, Lilly USA, LLC. “This registry affirms our ongoing commitment to assess the safety profile of ixekizumab in clinical practice settings.”

Psoriasis is a chronic, immunodysregulatory disease that appears on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis is not contagious. As many as 7.5 million Americans have psoriasis.

About the National Psoriasis Foundation

National Psoriasis Foundation (NPF) is the world’s largest nonprofit serving those with psoriasis and psoriatic arthritis. Our priority is to provide the information and services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our health education and advocacy initiatives, NPF has funded more than $13 million in psoriatic disease research grants and fellowships. Learn more about the Psoriasis Foundation at www.psoriasis.org or call 800-723-9166. Follow us on Facebook and Twitter .

PORTLAND, Ore. (March 28, 2016) — The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, a health research company that sponsors disease registries to advance medical research and improve patient care, is approaching the one-year anniversary of enrolling its first patient in April 2015.

To date, the registry has enrolled over 1,000 patients from 100 sites, where dermatologists assess patients every six months during routine visits and fill out a comprehensive questionnaire. Patients participating in the registry will be tracked for at least eight years, and the information collected will be used by researchers to compare the safety and effectiveness of psoriasis treatments, study diseases associated with psoriasis, and better understand the natural history of the disease.

“The achievement of these milestones demonstrates the potential impact of this unique resource for the psoriasis community, providing us with real world data on novel psoriasis treatments,” said Dr. Mark Lebwohl, scientific co-director of the Corrona Psoriasis Registry, and chairman emeritus of the NPF Medical Board.

The registry continues to recruit dermatologists who are treating people with moderate to severe psoriasis with biologics or systemic medications. Please email psoriasis@corrona.org for more information. Through this registry, Corrona LLC, expects over 200 dermatology sites to be added to their expansive network of sites.

“We are honored to have the commitment and active participation of 100 dermatology practices across the United States,” said Dr. Jeffrey Greenberg, chief scientific officer of Corrona, LLC. “The contribution by dermatologists collecting data will allow us to study comparative effectiveness and safety of newly approved therapies for their patients with psoriasis.”

Psoriasis is a chronic, immunodysregulatory disease that appears on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis is not contagious. Psoriasis is the most common autoimmune disease in the U.S. As many as 7.5 million Americans have psoriasis.

About the National Psoriasis Foundation

National Psoriasis Foundation (NPF) is the world’s largest nonprofit serving those with psoriasis and psoriatic arthritis. Our priority is to provide the information and services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our health education and advocacy initiatives, NPF has funded more than $13 million in psoriatic disease research grants and fellowships. Learn more about the Psoriasis Foundation at www.psoriasis.org or call 800-723-9166. Follow us on Facebook and Twitter .

SOUTHBOROUGH, MA ― Corrona, a leader in real world evidence and consulting in the auto-immune field, announced today that Richard (Rick) G. Jung has been elected as a member of the Board of Directors of the company. Corrona is a portfolio company of the health care investment firm, Great Point Partners, based in Greenwich CT.

Rick is currently serving as CEO and Chairman of Clinicient, a leading provider of automated, integrated revenue and clinical cycle services to physical, speech, occupational and rehabilitation therapy markets, based in Portland, OR.

“I am thrilled that Rick will be joining the Corrona Board of Directors. He has a great background that compliments that of our existing Board members. His experience in the electronic medical record space will be invaluable to us as we start to look at opportunities to link related data sources and increase the value we bring to our clients,” said Raymond H. Hill, Executive Chairman of Corrona.

Noah Rhodes, Managing Director of Great Point Partners noted “Rick possesses a unique and diverse background in health care. We are excited about his contributions to the Corrona Board of Directors as the company continues its next chapter of growth.”

“I am excited to be joining the Board of Directors of Corrona,” said Mr. Jung, “Corrona is doing innovative work with real world patient and clinical data in the autoimmune disease space. With access to leading observational data sets, Corrona is well positioned to help companies understand how their drugs are used in the real world.”

Mr. Jung is a member of the Board of Directors of Clinicent, where he has served since 2007. He previously was President and CEO of HealthFx, and COO of Medsphere Systems Corp. Earlier on in his career he served at both athenahealth, and US Healthcare.

About Corrona

Corrona was founded in 2000 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides data and research results to all biopharmaceutical companies with an interest in particular therapeutic areas of coverage. Corrona data is used to assist in comparative effectiveness, post market safety reporting, and commercial applications. Corrona is advised by experienced academic and clinical physicians throughout the country with a wide range of experiences. Read more at www.corrona.org.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point Partners at 203-971-3300 or www.gppfunds.com.